Liquidia (Liquidia) ROCE %

: -102.33% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Liquidia's annualized ROCE % for the quarter that ended in Dec. 2023 was -102.33%.

Liquidia ROCE % Historical Data

The historical data trend for Liquidia's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => -99.23 [4] => -84.29 [5] => -38.83 [6] => -37.41 [7] => -65.61 )

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-99.23

-84.29

-38.83

-37.41

-65.61

Liquidia Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-19.01	-35.04	-78.82	-55.67	-102.33

Liquidia ROCE % Calculation

Liquidia's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-72.229	/	( ( (129.198 - 8.8)	+	(118.332 - 18.55) )	/ 2 )
	=	-72.229	/	( (120.398	+	99.782)	/ 2 )
	=	-72.229	/	110.09
	=	-65.61 %

Liquidia's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-101.952	/	( ( (111.641 - 12.156)	+	(118.332 - 18.55) )	/ 2 )
	=	-101.952	/	( ( 99.485	+	99.782 )	/ 2 )
	=	-101.952	/	99.6335
	=	-102.33 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Liquidia (NAS:LQDA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Liquidia ROCE % Related Terms

Thank you for viewing the detailed overview of Liquidia's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia (Liquidia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LT4:Germany LT4:Germany

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

Executives

Rajeev Saggar	officer: Chief Medical Officer	419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair	officer: V.P. Crp Dvlpmnt and Strtgy	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs	director
Caligan Partners Lp	director, 10 percent owner, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe	officer: Chief Operations Officer	C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw	officer: SVP, Commercial	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta	officer: Chief Financial Officer	7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler	officer: General Counsel	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin	director	419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh	director	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin	director	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch	director	285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880